06.02.25 -- STREAM Edition: Evolve Or Fade Away? Biotech's Outsourcing Moment In Trump's Tariff Tangle

Explore how leveraging the right technologies and strategies early in development can help to optimize candidate selection, aid progression to cell line development, enhance manufacturability, and reduce downstream risk. We highlight common pitfalls and provide actionable strategies to accelerate the translation of biologic candidates from late discovery to first-in-human studies. Click here to learn more.

Leverage the power of Tandem Mass Tags (TMT) quantitative proteomics to gain deep insights into cellular dynamics, disease mechanisms, and drug targeting.

Pharma product release ensures drug quality, safety, and regulatory compliance by evaluating manufacturing and quality processes. It’s a critical process essential for FDA approval and patient safety.

Review a modeling approach employing artificial neural networks using experimental factors combined with simulation-derived parameters plus viscosity data from 27 highly concentrated mAbs.

Despite their potential to revolutionize treatment paradigms, antibody-drug conjugates (ADCs) face challenges that companies must tackle for successful development.

Formulations require flexibility to support adaptive sterile manufacturing and an integrated approach for a path from development, to small batch manufacturing, to commercialization.

See how our expertise in formulation and process development can ensure a seamless scale-up from laboratory to full-scale production of lyophilized injectable products.

A miscalculated analytical approach can be costly to develop, perform, and maintain. Many organizations also lack appropriate resources to create optimal testing methods and protocols.

Proper packing of MabSelect resins is crucial for efficient chromatography. Verified methods promote stability, optimal flow, and reproducibility across scales using automated tools.

This discussion among experts examines ways to push the envelope of expression system technology and process characterization while maximizing user transparency.

Discover how a long-standing global innovator is advancing healthcare, sustainability, and economic progress across China through integrated R&D, manufacturing, and local partnerships.

Whether you're navigating the challenges of complex biologics or seeking a faster path to the clinic, this discussion sheds light on how innovation in CLD can be a game-changer for your pipeline.

Tara Lorenz, Sr. Director of Commercial Operations, speaks on our latest investments and expanded fill/finish capabilities and capacity for small molecules, biologics, and other sterile injectable products.

With mounting pressure to accelerate timelines, choosing a CDMO that boosts capacity and streamlines processes through innovation is key to maintaining quality.

Simon Westbrook formed Levicept to develop an idea for a complex fusion chimera protein he believed could interrupt the neurotrophin pathway, and being a true virtual company, he needed a CDMO.

We implement a system-wide QbD approach to different phases of a clinical or drug product, including raw materials, in-process, batch release, and stability / shelf-life evaluation.